Pharmaceutical

Former Moderna Chief Development Officer Melanie Ivarsson OBE Joins PhaseV’s Scientific Advisory Board

Veteran Global Clinical Leader, Honored for Helping Develop One of the First COVID Vaccines, to Support Rollout of PhaseV's New…

6 months ago

PhaseV Announces New ClinOps AI Platform: Transforming Clinical Trial Operations with Precision-Guided Site Selection

Powered by Causal AI and Real-Time Patient-Level Data and Analytics, the ClinOps Platform Enables Faster and Smarter Decision Making Across…

6 months ago

GE HealthCare announces cash dividend for second quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per…

6 months ago

GE HealthCare announces cash dividend for second quarter of 2025

CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per…

6 months ago

LiveWorld Releases First-Ever AI Brand Reputation Index for Leading OTC Brands

Study highlights how AI tools like ChatGPT are shaping reputation and consumer perception of leading OTC brandsCAMPBELL, Calif. and NEW…

6 months ago

Inmagene Doses First Patient in the ADAPTIVE Phase 2b Trial of IMG-007, a Nondepleting Anti-OX40 mAb with an Extended Half-life, in Patients with Moderate-to-Severe Atopic Dermatitis

The ADAPTIVE Phase 2b trial evaluates multiple dose regimens of IMG-007 in patients with moderate-to-severe atopic dermatitisTopline data expected in…

6 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Phase 2 study of…

6 months ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance…

6 months ago

Earth Science Tech, Inc. Qualifies for and Joins New OTCID Tier

Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC: ETST) (“ETST” or the “Company”), a strategic…

6 months ago

Oragenics, Inc. Announces Pricing of Public Offering of up to $20 Million of Preferred Stock and Warrants

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…

6 months ago